
Chong Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1920400/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103.	27.8	1,769
2	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	14.3	1,437
3	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	27.8	702
4	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110.	27.8	501
5	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF- $\hat{1}^2$ Receptor Signaling. Cell, 2012, 151, 937-950.	28.9	371
6	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	6.4	266
7	Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nature Biotechnology, 2011, 29, 542-546.	17.5	207
8	EGFR activation limits the response of liver cancer to lenvatinib. Nature, 2021, 595, 730-734.	27.8	183
9	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends in Biochemical Sciences, 2014, 39, 465-474.	7.5	134
10	RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports, 2014, 8, 1475-1483.	6.4	103
11	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	6.4	61
12	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458.	12.0	36
13	Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant. Npj Breast Cancer, 2022, 8, .	5.2	1